Ian,

As you are aware much of our data is to demonstrate effectiveness in gramoxone formulations and it is these studies rather than toxicology of emetic per se which has been the main emphasis of regulatory submissions. Plus at least one review of the human data.

The database on the emetic per se is relatively old and limited. Currently being reviewed - a task we had identified previously to decide if we needed to update any studies for longer term maintenance of registrations.

Bayer would need to demonstrate effectiveness in their formulations since formulation type can influence availability and effectiveness would depend upon site of absorption of the aldicarb in the gi tract.

Assume you do not need bibliography of studies available etc at this time.

Mike